Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.58 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937675 | 0.96 | GPR119 (0.62) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6934156 | 0.90 | GPR119 (0.74) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6933732 | 0.87 | GPR119 (0.64) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6935080 | 0.85 | GPR119 (0.66) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6932235 | 0.85 | GPR119 (0.62) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6937679 | 0.83 | GPR119 (0.63) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6934776 | 0.83 | GPR119 (0.66) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6936782 | 0.83 | GPR119 (0.62) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL6934765 | 0.82 | GPR119 (0.61) | GPR119PDE3BPDE3APDE4APDE4B | |
| Domipizone SCHEMBL1814940 | 0.79 | PDE4B (0.69) | GPR119PDE3BPDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-0738715-B1 | Arylalkyl-pyridazinones | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6399611-B1 | 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | GPR119 2343/4885PDE3B 4/4885PDE3A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.